Showing results (71-80 of 84) with videos related to
Sort By:
Pageof 9
Molecular Oncology|December 26, 2022
ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITDYu Qian, Xiang Zhang, Shihui Mao, et al.Annals of Hematology|January 25, 2023
FLOT1 knockdown inhibits growth of AML cells through triggering apoptosis and pyroptosisShihui Mao, Yu Qian, Wenwen Wei, et al.Journal of Molecular Medicine (Berlin, Germany)|February 10, 2024
High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage responseJiajia Pan, Yungui Wang, Shujuan Huang, et al.Frontiers of Medicine|May 2, 2023
ACSL5, a prognostic factor in acute myeloid leukemia, modulates the activity of Wnt/β-catenin signaling by palmitoylation modificationWenle Ye, Jinghan Wang, Jiansong Huang, et al.Ebiomedicine|June 24, 2021
MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathwayQing Ling, Fenglin Li, Xiang Zhang, et al.Cancer Letters|July 17, 2019
Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemiaShujuan Huang, Jiajia Pan, Jing Jin, et al.Molecular Carcinogenesis|July 26, 2023
circSLC25A13 acts as a ceRNA to regulate AML progression via miR-616-3p/ADCY2 axisWenwen Wei, Jiajia Pan, Jinghan Wang, et al.Ebiomedicine|November 26, 2018
High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effectsXia Li, Chenying Li, Jingrui Jin, et al.Thrombosis and Haemostasis|September 22, 2020
Ibrutinib Suppresses Early Megakaryopoiesis but Enhances Proplatelet FormationJiansong Huang, Shujuan Huang, Zhixin Ma, et al.Cancer Medicine|January 9, 2023
Dihydropyrimidinase-like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemiaFenglin Li, Qing Ling, Jiaying Lian, et al.Pageof 9